Patents Assigned to AB BIOSCIENCES, INC.
-
Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use
Patent number: 11801286Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: GrantFiled: March 29, 2022Date of Patent: October 31, 2023Assignee: AB Biosciences, Inc.Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
Patent number: 11304994Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: GrantFiled: March 29, 2017Date of Patent: April 19, 2022Assignee: AB Biosciences, Inc.Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Patent number: 9624290Abstract: The present invention provides methods for making novel, rationally designed lowered affinity antibodies. The methods of the present invention make antibodies that have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall (3) dimensional antibody structure. Using the antibodies made using methods of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: GrantFiled: January 28, 2011Date of Patent: April 18, 2017Assignee: AB BIOSCIENCES, INC.Inventor: Hsiu-Ching Chang
-
Patent number: 9494597Abstract: The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: GrantFiled: April 2, 2013Date of Patent: November 15, 2016Assignee: AB BIOSCIENCES, INC.Inventors: Hsiu-Ching Chang, Yen-Ming Hsu, Jeng-Shin Lee
-
Publication number: 20140066600Abstract: The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: ApplicationFiled: August 8, 2013Publication date: March 6, 2014Applicant: AB Biosciences, Inc.Inventor: Hsiu-Ching Chang
-
Patent number: 8530629Abstract: The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: GrantFiled: January 29, 2010Date of Patent: September 10, 2013Assignee: AB Biosciences, Inc.Inventor: Hsiu-Ching Chang
-
Publication number: 20120329995Abstract: The present invention provides methods for making novel, rationally designed lowered affinity antibodies. The methods of the present invention make antibodies that have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall (3) dimensional antibody structure. Using the antibodies made using methods of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: ApplicationFiled: January 28, 2011Publication date: December 27, 2012Applicant: AB BIOSCIENCES, INC.Inventor: Hsiu-Ching Chang
-
Publication number: 20110287533Abstract: The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: ApplicationFiled: January 29, 2010Publication date: November 24, 2011Applicant: AB BIOSCIENCES, INC.Inventor: Hsiu-Ching Chang